Evidence map›Paper›PMID 28625831›Full record

ReviewAdvanced drug delivery reviews2017

Engineering challenges for brain tumor immunotherapy.

Johnathan G Lyon, Nassir Mokarram, Tarun Saxena, Sheridan L Carroll, Ravi V Bellamkonda

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Review
  3. Targeting the COX-2/PGECancer immunology, immunotherapy : CII · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Applications of organoid technology to brain tumors.CNS neuroscience & therapeutics · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Immunotherapy for glioblastoma: the promise of combination strategies.Journal of experimental & clinical cancer research : CR · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Johnathan G LyonDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC 27708-0271, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory School of Medicine, UA Whitaker Building, 313 Ferst Drive, Atlanta, GA 30332, USA.
Nassir MokarramDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC 27708-0271, USA.
Tarun SaxenaDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC 27708-0271, USA.
Sheridan L CarrollDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC 27708-0271, USA.
Ravi V BellamkondaDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC 27708-0271, USA. Electronic address: ravi@duke.edu.

Funding

Research Training Program Plan on Cell and Tissue Engineering (CTEng)T32GM008433 · NIGMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 1991 to 2021
$7.1M
Immunoengineering Nerve RepairR01NS093666 · NINDS · GEORGIA INSTITUTE OF TECHNOLOGY · PI BELLAMKONDA, RAVI V. · 2015 to 2019
$1.7M
A Rational Approach to Stimulating Peripheral Nerve Regeneration Across CriticallR01NS065109 · NINDS · GEORGIA INSTITUTE OF TECHNOLOGY · PI BELLAMKONDA, RAVI V. · 2009 to 2013
$1.6M
NIGMS NIH HHS T32 GM008433NINDS NIH HHS R01 NS065109NINDS NIH HHS R01 NS093666
6 · The paper itself

Abstract

Malignant brain tumors represent one of the most devastating forms of cancer with abject survival rates that have not changed in the past 60years. This is partly because the brain is a critical organ, and poses unique anatomical, physiological, and immunological barriers. The unique interplay of these barriers also provides an opportunity for creative engineering solutions. Cancer immunotherapy, a means of harnessing the host immune system for anti-tumor efficacy, is becoming a standard approach for treating many cancers. However, its use in brain tumors is not widespread. This review discusses the current approaches, and hurdles to these approaches in treating brain tumors, with a focus on immunotherapies. We identify critical barriers to immunoengineering brain tumor therapies and discuss possible solutions to these challenges.

Indexed as

BioengineeringAdoptive TransferAnimalsBrain NeoplasmsGlioblastomaHumansImmunotherapyVaccinesVaccinesBlood-brain barrierBrain cancerGlioblastomaImmunoengineeringImmunomodulationImmunotherapyLymphaticsNeuroimmunologyNeurooncoimmunologyTumor-associated microglia

Identifiers

PMID28625831
PMCPMC5870902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.